Episode 593: Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
Dec 20 2024
Length: 27 mins
Podcast

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

Episode 593: Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?

Listen for free

View show details

Summary
In episode 593, Mike and James invite Samantha Moe back to talk about a newer agent for osteoporosis. So, if you want to know all the evidence for romosozumab, tune in and all will be revealed about the benefits and harms. Show notes 1) Tools for Practice Tony Romo-sozumab: Winning touchdown in osteoporosis or interception […]

Show More Show Less

Only £0.99 a month for the first 3 months. Pay £0.99 for the first 3 months, and £7.99/month thereafter. Renews automatically. Terms apply. Start my membership

Show More Show Less

What listeners say about Episode 593: Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.co.uk reviews

Amazon reviews

No Reviews are Available

Report a review on Amazon